Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.23, Briefing.com reports. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same period last year, the firm earned ($1.40) earnings per share. The company's revenue for the quarter was up 54.8% compared to the same quarter last year.
Alnylam Pharmaceuticals Trading Up 1.3 %
NASDAQ ALNY traded up $2.02 during trading on Friday, hitting $152.33. 452,157 shares of the company's stock were exchanged, compared to its average volume of 763,489. The stock's 50 day moving average price is $149.76 and its two-hundred day moving average price is $165.25. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The company has a market cap of $19.19 billion, a PE ratio of -42.22 and a beta of 0.41.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on ALNY. Cantor Fitzgerald reissued a "neutral" rating and issued a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their target price for the company from $230.00 to $173.00 in a research report on Friday, February 16th. JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a "neutral" rating in a research report on Thursday, February 1st. Needham & Company LLC reissued a "buy" rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $215.88.
Get Our Latest Stock Report on Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
